Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Sir William Dunn School of Pathology have identified a mechanism by which the rod-shaped bacterium, Pseudomonas aeruginosa, can evade antibiotics by surrounding its cells with a self-made protective casing.

None

Pathogenic rod-shaped bacteria are responsible for causing many human infectious diseases such as meningitis and cholera. A wide variety of these bacteria are becoming tolerant to current antibiotics, rendering treatments ineffective. It is therefore of critical importance to understand the mechanisms used by these bacteria to evade antibiotics.

Abul Tarafder and colleagues from Tanmay Bharat’s group in the Dunn School have identified a mechanism by which the rod-shaped bacterium, Pseudomonas aeruginosa, can evade antibiotics by surrounding its cells with a self-made protective casing. The bacteria produce a symbiotic filament-shaped phage, Pf4, that phase-separates into spindle-shaped liquid crystals. These encapsulate bacterial cells, preventing effective concentrations of antibiotic reaching the cell, thus ensuring bacterial survival. Interestingly, the authors found that this phage-mediated antibiotic tolerance mechanism is profoundly influenced by biophysical size and shape complementarity rather than the biochemical properties of the phage and bacteria, as the phage liquid crystals could encapsulate inanimate rods of comparable size to bacteria.

Read more on the Sir William Dunn School of Pathology website

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.